18F-αvβ6-BP for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This clinical trial studies the side effects of 18F-alphavbeta6-binding-peptide and how well it works in imaging patients with primary or cancer that has spread to the breast, colorectal, lung, or pancreatic. Radiotracers, such as 18F-alphavbeta6-binding-peptide, may improve the ability to locate cancer in the body.
Who Is on the Research Team?
Julie Sutcliffe
Principal Investigator
University of California, Davis
Are You a Good Fit for This Trial?
This trial is for people with primary or metastatic breast, colorectal, lung, or pancreatic cancer who can stay still for PET scans and have a good performance status. It's not for those with severe kidney/liver issues, very short life expectancy, pregnant/breastfeeding women, recent investigational drug use, or inability to undergo PET/CT scans.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 18F-alphavbeta6-BP intravenously and undergo 4 PET scans over 30 minutes each at 30, 60, 120, and 180 minutes post-injection
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- 18F-αvβ6-BP
Find a Clinic Near You
Who Is Running the Clinical Trial?
Julie L. Sutcliffe, Ph.D
Lead Sponsor
National Cancer Institute (NCI)
Collaborator